Core Insights - OS Therapies, Inc. has entered into agreements for the commercial manufacture of OST-HER2, an immunotherapy candidate aimed at preventing recurrence of lung metastatic osteosarcoma [1] - The company plans to submit a Biologics Licensing Authorization (BLA) application to the FDA for accelerated or conditional approval following a recent FDA meeting [2] - The Phase 2b trial data for OST-HER2 shows statistically significant results in the primary endpoint of 12-month event-free survival (EFS) compared to historical controls [3] - There is a strong trend favoring OST-HER2-treated patients in overall survival at the 1-year and 2-year interim time points of the ongoing study [4] - OS Therapies has acquired immuno-oncology programs and related intellectual property from Ayala Pharmaceuticals for $0.5 million in cash and $7.5 million in common shares [4][5] - The company completed a $7.1 million financing, providing sufficient cash runway into 2026, including payments to Ayala [5] - OSTX stock has increased by 28.6%, reaching $2.58 [5]
Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer Drug For Rare Type Of Bone Cancer